Table of Contents

• Overview of CVN424 Clinical Research
• Understanding Parkinson’s Disease and OFF Time
• Phase 2 Trial Design and Structure
• Patient Population and Enrollment
• Dosing Regimens and Administration
• Primary Outcomes and Measurements
• Clinical Significance and Research Goals

Overview of CVN424 Clinical Research

CVN424, also known by its chemical name 1-[2-[4-(2,4-DIFLUOROPHENOXY)PIPERIDIN-1-YL]-3-[[(3R)-OXOLAN-3-YL]AMINO]-7,8-DIHYDRO-5H-PYRIDO[3,4-B]PYRAZIN-6-YL]ETHANONE, is an investigational drug currently being studied for the treatment of Parkinson’s disease^[1]. The clinical development program for CVN424 focuses on addressing one of the most challenging aspects of Parkinson’s disease management: reducing OFF time experienced by patients.

The current clinical trial program represents an important step in evaluating whether CVN424 can provide meaningful benefits to patients living with Parkinson’s disease^[1]. The research is designed to generate evidence about the drug’s effectiveness and safety profile in a controlled clinical setting.

Understanding Parkinson’s Disease and OFF Time

Parkinson’s disease is a progressive neurological disorder that affects movement and motor control^[1]. Patients with Parkinson’s disease often experience a range of symptoms including tremors, muscle stiffness, slowness of movement, and balance problems. As the disease progresses, managing these symptoms becomes increasingly complex.

One of the most significant challenges in Parkinson’s disease management is the phenomenon known as OFF time^[1]. OFF time refers to periods during the day when a patient’s medications are not working effectively, and Parkinson’s symptoms return or worsen. During these periods, patients may experience:

• Increased tremors: Involuntary shaking that becomes more pronounced when medications wear off
• Muscle rigidity: Stiffness and tension in muscles that makes movement difficult and uncomfortable
• Bradykinesia: Slowness of movement that affects daily activities and quality of life
• Balance difficulties: Increased risk of falls and challenges with coordination
• Reduced mobility: Difficulty performing routine tasks and maintaining independence

The CVN424 clinical trial specifically targets the reduction of OFF time, aiming to help patients maintain better symptom control throughout the day^[1]. By potentially extending the periods when medications work effectively (known as ON time), CVN424 may improve patients’ ability to perform daily activities and enhance their overall quality of life.

Phase 2 Trial Design and Structure

The CVN424 study is classified as a Phase 2 clinical trial, which represents the second major stage of drug development in humans^[1]. Phase 2 trials are designed to evaluate both the efficacy (whether the drug works) and safety (whether the drug is well-tolerated) in a larger group of patients than Phase 1 studies.

This particular trial is an interventional study, meaning that researchers actively administer CVN424 to participants and measure the results^[1]. The study design includes a comparison with placebo, which is an inactive substance that looks identical to the actual medication but contains no therapeutic ingredient. This comparison is essential for determining whether any observed benefits are truly due to CVN424 rather than other factors such as the placebo effect or natural disease variation.

The trial has received authorized status, indicating that regulatory authorities have reviewed and approved the study protocol^[1]. This authorization confirms that the trial meets necessary safety and ethical standards for proceeding with patient enrollment and treatment.

The study duration includes a 12-week treatment period, during which participants receive either CVN424 or placebo^[1]. This timeframe allows researchers to observe both short-term effects and the development of sustained therapeutic benefits over time. The 12-week period is considered sufficient to evaluate changes in OFF time while also monitoring for any safety concerns that may emerge with continued use.

Patient Population and Enrollment

The Phase 2 CVN424 trial plans to enroll a total of 353 participants with Parkinson’s disease^[1]. This substantial enrollment number is designed to provide statistically meaningful data about the drug’s effectiveness and safety profile. A larger patient population helps researchers:

• Detect treatment effects: Identify whether CVN424 produces clinically significant improvements in OFF time compared to placebo
• Assess consistency: Determine if the drug works similarly across different patients with varying disease characteristics
• Identify safety signals: Monitor for adverse events and understand how common or rare they may be
• Evaluate subgroups: Analyze whether certain patient characteristics influence treatment response
• Support regulatory decisions: Generate sufficient evidence for regulatory authorities to evaluate the drug’s potential benefits and risks

The trial specifically focuses on patients with Parkinson’s disease who experience OFF time^[1]. This target population represents individuals who continue to have periods of inadequate symptom control despite current treatment, indicating an unmet medical need that CVN424 aims to address.

Dosing Regimens and Administration

The CVN424 trial investigates two different dose levels to determine the optimal therapeutic approach^[1]. The doses being evaluated are:

• 75 mg CVN424: A lower dose administered orally once daily
• 150 mg CVN424: A higher dose administered orally once daily

Both doses are formulated as film-coated tablets for oral administration^[1]. Film-coated tablets offer several advantages for patients, including easier swallowing, protection of the active ingredient from moisture and light, and potentially improved stability. The oral route of administration provides convenience for patients, allowing them to take the medication at home without requiring injections or other more complex delivery methods.

The once-daily dosing schedule is designed to simplify the treatment regimen and improve patient adherence^[1]. Many Parkinson’s disease medications require multiple doses throughout the day, which can be burdensome for patients and caregivers. A once-daily medication may be easier to remember and incorporate into daily routines, potentially improving treatment compliance.

Testing two different doses allows researchers to evaluate the dose-response relationship^[1]. This means determining whether a higher dose provides greater benefits, whether both doses are similarly effective, or whether one dose offers the best balance between efficacy and tolerability. This information is crucial for identifying the optimal dose for future clinical development and potential clinical use.

Primary Outcomes and Measurements

The primary outcome of the CVN424 Phase 2 trial is the change from baseline to week 12 in average daily OFF time for patients receiving 150 mg CVN424 compared to placebo^[1]. This measurement is normalized to waking hours, meaning it accounts for the total time patients are awake each day, providing a standardized way to compare results across participants who may have different sleep schedules.

To measure OFF time accurately, patients use motor diaries^[1]. Motor diaries are structured records that patients complete throughout the day, documenting their symptom status at regular intervals. Patients typically categorize their state as:

• ON time without troublesome dyskinesia: Periods when medications are working well and symptoms are controlled without problematic involuntary movements
• ON time with troublesome dyskinesia: Periods when medications are working but causing bothersome involuntary movements
• OFF time: Periods when medications are not working effectively and Parkinson’s symptoms return
• Sleep time: Periods when the patient is asleep

The use of motor diaries provides real-world data about how patients experience their symptoms throughout the day in their normal environment^[1]. This patient-reported outcome is considered highly valuable because it captures the actual impact of treatment on daily functioning from the patient’s perspective.

The baseline measurement represents each patient’s OFF time before starting CVN424 or placebo^[1]. By comparing the week 12 measurement to baseline, researchers can determine whether CVN424 produces a meaningful reduction in OFF time. The comparison to placebo is essential for determining whether any observed changes are specifically due to CVN424’s therapeutic effects rather than other factors such as natural disease fluctuation, placebo effects, or changes in concomitant medications.

The focus on the 150 mg dose for the primary outcome suggests that researchers hypothesize this higher dose may provide the most robust therapeutic benefit^[1]. However, data from both the 75 mg and 150 mg doses will likely be analyzed to understand the full dose-response profile and identify the optimal therapeutic dose.

Clinical Significance and Research Goals

The primary objective of the CVN424 clinical trial is to assess the efficacy of CVN424 dosed once daily, compared to placebo, for change in OFF time in Parkinson’s disease^[1]. This research goal addresses a significant unmet need in Parkinson’s disease management, as many patients continue to experience troublesome OFF time despite available treatments.

The clinical significance of reducing OFF time extends beyond simple symptom control. Decreased OFF time can potentially lead to:

• Improved quality of life: More consistent symptom control allows patients to engage in daily activities with greater confidence and independence
• Enhanced functional capacity: Reduced OFF time means more hours during the day when patients can move more easily and perform tasks
• Better treatment satisfaction: Patients who experience less OFF time may feel more confident in their treatment regimen
• Reduced caregiver burden: More predictable symptom control can ease the demands on family members and caregivers
• Potential for maintained independence: Better motor function throughout the day may help patients maintain their ability to live independently longer

The Phase 2 trial represents a critical step in the development pathway for CVN424^[1]. If the trial demonstrates that CVN424 effectively reduces OFF time with an acceptable safety profile, it could advance to Phase 3 trials, which involve even larger patient populations and are designed to provide definitive evidence of efficacy and safety for regulatory approval.

The once-daily oral formulation of CVN424 may offer practical advantages over some existing Parkinson’s disease treatments^[1]. Simplifying the dosing schedule could improve patient adherence and reduce the complexity of managing multiple medications throughout the day. For patients already taking several medications for Parkinson’s disease and other conditions, a once-daily option may be particularly valuable.

The trial’s design, with its focus on objective measurements through motor diaries and comparison to placebo, follows rigorous scientific standards^[1]. This methodological approach ensures that the results will provide reliable evidence about CVN424’s potential therapeutic value. The 12-week duration allows for assessment of both initial response and sustained benefit over time, while also providing an opportunity to monitor safety throughout the treatment period.

As the trial progresses through enrollment and treatment phases, the data generated will contribute to the broader understanding of how to effectively manage OFF time in Parkinson’s disease^[1]. Regardless of the specific outcomes, the research will add to the scientific knowledge base and may inform future treatment development efforts for this challenging aspect of Parkinson’s disease management.